Loading…
Ocugen, Inc. is projected to rise to $1.39 by 2027, a +1% move from its current price of $1.38. OCGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.33 | $1.38 | $1.43 | -0.02% |
| May 30 | $1.32 | $1.38 | $1.45 | -0.05% |
| May 31 | $1.30 | $1.38 | $1.46 | -0.07% |
| Jun 1 | $1.29 | $1.38 | $1.47 | -0.10% |
| Jun 2 | $1.28 | $1.38 | $1.49 | -0.12% |
| Jun 3 | $1.27 | $1.38 | $1.50 | -0.15% |
| Jun 4 | $1.26 | $1.38 | $1.51 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.26 | $1.38 | $1.51 | -0.17% |
| Week 2 | $1.21 | $1.38 | $1.56 | -0.34% |
| Week 3 | $1.18 | $1.37 | $1.60 | -0.51% |
| Week 4 | $1.15 | $1.37 | $1.64 | -0.69% |
| Week 5 | $1.12 | $1.37 | $1.67 | -0.86% |
| Week 6 | $1.10 | $1.37 | $1.70 | -1.03% |
| Week 7 | $1.08 | $1.36 | $1.72 | -1.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ocugen, Inc. is a healthcare company focused on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. Its pipeline includes OCU400, a novel gene therapy candidate for retinal diseases currently in Phase 3 for retinitis pigmentosa and Phase 1/2 for Leber congenital amaurosis; OCU410 for dry age-related macular degeneration in Phase 1/2; OCU410ST for Stargardt disease in Phase 1/2; OCU200, a novel recombinant fusion protein for diabetic macular edema, diabetic retinopathy, and wet AMD; NeoCart for knee cartilage repair; and OCU500, OCU510, and OCU520 vaccines in development.
The company is developing OCU500 with National Institute of Allergy and Infectious Diseases for early studies, and has a strategic partnership with CanSino Biologics for manufacturing modifier gene therapy candidates. Ocugen was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. (OCGN) is a healthcare company with a current price of $1.34 and a market cap of $453.62M, ranking 3112 by market size. The near-term outlook reflects a neutral stance, with a 30-day technical picture showing mixed signals and a modest price path ahead.
A major floor 37.2% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 44.2% above — a clean break opens room to run.
A major ceiling 79.7% above — clearing it would confirm fresh momentum.
Key OCGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OCGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.35 | Buy | $1.36 | Buy |
| MA 10 | $1.37 | Buy | $1.39 | Sell |
| MA 20 | $1.48 | Sell | $1.47 | Sell |
| MA 50 | $1.72 | Sell | $1.61 | Sell |
| MA 100 | $1.69 | Sell | $1.62 | Sell |
| MA 200 | $1.51 | Sell | $1.50 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.60 | Neutral |
| Stoch RSI (14) | 92.90 | Sell |
| CCI (20) | -58.00 | Neutral |
| Williams %R (14) | -61.90 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -8.61 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 38.10 | Neutral |
| TRIX (15) | -0.98 | Sell |
| Awesome (5,34) | -0.26 | Sell |
| Ultimate (7,14,28) | 43.39 | Neutral |
| Momentum (10) | -0.09 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 1.35 | Buy |
| ADX (14) | 23.64 | Sell |
| ATR (14) | 0.05 | Info |
RSI14 is 30, indicating neutral momentum. The 50-day simple moving average is $1.76 and the 200-day simple moving average is $1.51. A near-term support level is at $1.30 and a resistance level at $1.99, framing a 30-day range from $1.06 to $1.69.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.30 | $1.38 | $1.91 | 0% | Neutral | |
| $1.08 | $1.39 | $1.92 | +1% | Neutral | |
| $1.27 | $1.69 | $2.43 | +22% | Bullish | |
| $1.52 | $2.08 | $3.09 | +51% | Bullish | |
| $1.52 | $2.14 | $3.27 | +55% | Bullish | |
| $1.64 | $2.36 | $3.70 | +71% | Bullish | |
| $1.52 | $2.24 | $3.58 | +62% | Bullish | |
| $1.44 | $2.17 | $3.53 | +57% | Bullish | |
| $1.77 | $2.72 | $4.53 | +97% | Bullish | |
| $2.01 | $3.15 | $5.33 | +128% | Bullish | |
| $2.19 | $3.74 | $6.79 | +171% | Bullish | |
| $3.95 | $7.92 | $15.91 | +474% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.30 | $1.38 | $1.62 | +0.00% |
| June 2026 | $1.12 | $1.33 | $1.61 | -3.97% |
| July 2026 | $1.13 | $1.35 | $1.66 | +1.83% |
| August 2026 | $1.15 | $1.39 | $1.73 | +2.79% |
| September 2026 | $1.12 | $1.36 | $1.72 | -1.83% |
| October 2026 | $1.12 | $1.37 | $1.74 | +0.56% |
| November 2026 | $1.18 | $1.45 | $1.86 | +5.70% |
| December 2026 | $1.20 | $1.48 | $1.91 | +1.93% |
Click any year to see its month-by-month OCGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OCGN is projected to trade between $1.30 and $1.91, averaging $1.38 — a potential gain of 0% from today's $1.38. Price action looks broadly range-bound.
Ocugen, Inc.'s 2027 outlook centres on $1.39, within a $1.08 to $1.92 range. That is up +1% on the projected 2026 average. That marks a +1% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, OCGN could reach as high as $2.43, with a base case around $1.69 and support toward $1.27 — roughly +22% from $1.38. Momentum favours further upside here.
Expect OCGN to range from $1.52 to $3.09 through 2029. The $2.08 average target implies a +51% move from current prices. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The OCGN price prediction for 2030 points to an average of $2.14 (low $1.52, high $3.27) — a potential gain of +55% on today's $1.38. Momentum favours further upside here.
In 2031, OCGN is projected to trade between $1.64 and $3.70, averaging $2.36 — a potential gain of +71% from today's $1.38. That is up +10% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Ocugen, Inc.'s 2032 outlook centres on $2.24, within a $1.52 to $3.58 range. That is -5% versus the projected 2031 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2033, OCGN could reach as high as $3.53, with a base case around $2.17 and support toward $1.44 — roughly +57% from $1.38. Buyers look set to stay in control over this stretch.
Expect OCGN to range from $1.77 to $4.53 through 2034. The $2.72 average target implies a +97% move from current prices. That is up +26% on the projected 2033 average. Momentum favours further upside here.
The OCGN price prediction for 2035 points to an average of $3.15 (low $2.01, high $5.33) — a potential gain of +128% on today's $1.38. Buyers look set to stay in control over this stretch.
In 2040, OCGN is projected to trade between $2.19 and $6.79, averaging $3.74 — a potential gain of +171% from today's $1.38. That is up +19% on the projected 2035 average. Momentum favours further upside here.
Ocugen, Inc.'s 2050 outlook centres on $7.92, within a $3.95 to $15.91 range. That is up +112% on the projected 2040 average. That marks a +474% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in OCGN today (≈ 724.637681 OCGN) could be worth
$5,739.34
+$4,739.34 (+474%) by 2050 · US Dollar
Based on the average projected OCGN price of $7.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OCGNwould be worth at today's price.
$1,000 invested in OCGN on May 27, 2025 (≈ 1,043.841331 OCGN) would be worth
$1,440.5
+$440.5 (+44.1%) today · 1.44× · US Dollar
Based on a OCGN entry price of $0.958 vs. today's $1.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.36 | $1,014.71 | +1.5% |
| 1 month ago | $1.7 | $811.76 | -18.8% |
| 3 months ago | $1.87 | $737.97 | -26.2% |
| 6 months ago | $1.24 | $1,112.9 | +11.3% |
| 1 year ago | $0.958 | $1,440.5 | +44.1% |
| All time (5.0y) ago | $8.57 | $161.03 | -83.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OCGN forecast.
Our base-case forecast reaches $2.80 around 2035.
Implied market cap at $2.80: $947.86M
The year-by-year forecast shows a path from a neutral start in 2026 to a bullish mood in the following years. The 2026 average price is $1.34 with an ROI of 0% and a neutral sentiment. By 2029 the average price rises to $1.84 with an ROI of 37.4% and a bullish sentiment, and by 2030 the average is $1.89 with a 41.4% ROI.
The trajectory continues higher through 2031 ($2.07, 54.8%), 2032 ($1.91, 42.7%), 2034 ($2.25, 68.1%), and 2035 ($2.56, 91%). By 2040 the average reaches $2.95 with a 120.3% ROI, and by 2050 the average climbs to $6.17 with a 360.1% ROI, with a bullish sentiment. These estimates imply a substantial long-term upside potential, though they are not guarantees and depend on clinical/regulatory progress and other market factors.
Drivers include the ongoing and planned programs in the Ocugen pipeline and strategic partnerships; risks include typical biotech development and regulatory uncertainties.
Tap a question to reveal the answer.
The 2030 forecast lists an average price of $1.89 with an ROI of 41.4% and a bullish sentiment.
The forecast shows a mix of neutral and bullish years, with 2026 at $1.34 (0% ROI) and several years showing higher returns (e.g., 2029 at $1.84 with 37.4% ROI, 2030 at $1.89 with 41.4% ROI, and 2050 at $6.17 with 360.1% ROI). The path suggests potential upside but includes years of lower or negative returns and is not guaranteed.
Yes. The 2050 forecast shows a max of $12.63 with a 360.1% ROI.
RSI14 is 30 (neutral). The 50-day SMA is $1.76 and the 200-day SMA is $1.51. Near-term support is at $1.30 and resistance at $1.99, with a 30-day price range of $1.06 to $1.69.
Current price is $1.34 and market cap is $453.62M.
Ocugen, Inc. Community Discussion
0Share your Ocugen, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.